OmniAb's revenue jump, raised guidance, and Lilly deal boost cash outlook
Q2 revenue surges 243%, loss narrows, guidance raised OmniAb's second-quarter revenue jumped to $13.4 million from $3.9 million a year earlier, and its net loss shrank to $5.9 million from $15.9 million. Management raised full-year 2026 revenue guidance to $32–36 million. This shows the business is growing and losing less money, which supports a higher stock price.
This is the core financial result that directly improves OABI's earnings outlook and investor confidence.
Eli Lilly ion channel deal adds up to $370M in milestones OmniAb signed a global collaboration with Eli Lilly for an ion channel program. OmniAb gets an upfront payment and could receive up to $370 million in milestone payments plus royalties on sales. This validates OmniAb's technology and brings in cash without selling new shares, which is good for the stock.
The Lilly deal is a major new partnership that boosts OmniAb's cash and credibility, directly affecting its valuation.
Cash forecast raised to $49–53 million on licensing deals OmniAb now expects to end 2026 with $49–53 million in cash, up from a prior $37–41 million estimate, thanks to recent licensing deals including Lilly. More cash means the company can fund operations longer without needing to raise money by selling stock, which reduces risk for shareholders.
The higher cash outlook directly addresses funding concerns and lowers the risk of dilution, a key driver for a small biotech stock.
New partner agreements with Argenx and Rosa Therapeutics OmniAb signed new agreements with Argenx and Rosa Therapeutics, adding to its 110 active partners and 425 active programs. Growing demand for its antibody discovery platforms shows the business can keep attracting partners, which supports future milestone revenue and stock price.
New partnerships signal growing platform demand, a key long-term growth driver for OmniAb.